JP2003506447A5 - - Google Patents

Download PDF

Info

Publication number
JP2003506447A5
JP2003506447A5 JP2001515668A JP2001515668A JP2003506447A5 JP 2003506447 A5 JP2003506447 A5 JP 2003506447A5 JP 2001515668 A JP2001515668 A JP 2001515668A JP 2001515668 A JP2001515668 A JP 2001515668A JP 2003506447 A5 JP2003506447 A5 JP 2003506447A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
alkyl
alkylamino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001515668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003506447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/021579 external-priority patent/WO2001010859A1/en
Publication of JP2003506447A publication Critical patent/JP2003506447A/ja
Publication of JP2003506447A5 publication Critical patent/JP2003506447A5/ja
Pending legal-status Critical Current

Links

JP2001515668A 1999-08-10 2000-08-08 血管形成阻害活性をもつ置換ピリダジン類および縮合ピリダジン類 Pending JP2003506447A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
US09/371,322 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (2)

Publication Number Publication Date
JP2003506447A JP2003506447A (ja) 2003-02-18
JP2003506447A5 true JP2003506447A5 (https=) 2005-06-02

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001515668A Pending JP2003506447A (ja) 1999-08-10 2000-08-08 血管形成阻害活性をもつ置換ピリダジン類および縮合ピリダジン類

Country Status (19)

Country Link
EP (1) EP1208096B1 (https=)
JP (1) JP2003506447A (https=)
KR (1) KR20020019969A (https=)
CN (1) CN1378543A (https=)
AR (1) AR025068A1 (https=)
AT (1) ATE265448T1 (https=)
AU (1) AU775237B2 (https=)
BR (1) BR0013113A (https=)
CA (1) CA2381621A1 (https=)
CO (1) CO5180637A1 (https=)
DE (1) DE60010280T2 (https=)
ES (1) ES2219382T3 (https=)
IL (1) IL147885A0 (https=)
MX (1) MXPA02001324A (https=)
NO (1) NO20020569L (https=)
NZ (1) NZ517087A (https=)
PE (1) PE20010494A1 (https=)
WO (1) WO2001010859A1 (https=)
ZA (1) ZA200200691B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN100372535C (zh) * 2002-09-24 2008-03-05 诺瓦提斯公司 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
JP2006507319A (ja) * 2002-11-12 2006-03-02 ノバルティス アクチエンゲゼルシャフト 中皮腫の処置
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
ES2395877T3 (es) 2007-06-19 2013-02-15 Rynel, Inc. Materiales que comprenden partículas poliméricas solubles en agua y métodos para prepararlos y usarlos
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
WO2010017240A2 (en) * 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
JP2024505256A (ja) * 2021-01-28 2024-02-05 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
DE69533057T2 (de) * 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CN1660840A (zh) * 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物

Similar Documents

Publication Publication Date Title
JP2003506447A5 (https=)
RU2002111414A (ru) Замещенные пиридины и пиридазины, обладающие способностью ингибировать ангиогенез
RU2221798C2 (ru) Имидазонафтиридины, фармацевтическая композиция на их основе, способ стимуляции биосинтеза цитокина и промежуточные вещества
CO5200835A1 (es) Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
JP2002518384A5 (https=)
JP2005532287A5 (https=)
JP2007517044A5 (https=)
JP2004501940A5 (https=)
JPH11162650A5 (https=)
JP2001526218A5 (https=)
JP2008525416A5 (https=)
JP2004525888A5 (https=)
JP2002502874A5 (https=)
JP2006507235A5 (https=)
JP2022534702A5 (https=)
WO2001087845A3 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
JP2007505138A5 (https=)
JP2004530641A5 (https=)
JPH1180090A5 (https=)
JP2003206485A5 (https=)
JP2009530424A5 (https=)
JP2005505565A5 (https=)
JP2011520775A5 (https=)
JP2002532505A5 (https=)
JP2005535594A5 (https=)